ulcerative colitis
NICE recommends Celgene’s Ozanimod to treat ulcerative colitis
Nicole Raleigh
biological treatment, Celgene, conventional therapy, drug approval, NICE, Ozanimod, ulcerative colitis, Zeposia
0 Comment
Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials
Phil Taylor
Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, inflammatory bowel disease, Pfizer, ulcerative colitis, Zeposia
0 Comment
Second trial opens door for Lilly’s mirikizumab in ulcerative colitis
Phil Taylor
Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis
0 Comment
Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off
Phil Taylor
Bristol-Myers Squibb, etrasimod, Immunology and inflammation, Pfizer, ulcerative colitis, Zeposia
0 Comment
Lilly unveils mirikizumab data in ulcerative colitis as it preps filings
Phil Taylor
Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis
0 Comment
Flush with COVID cash, Pfizer tables $6.7bn bid for Arena
Phil Taylor
Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, M&A, Pfizer, ulcerative colitis, Zeposia
0 Comment
Failed IBD trial dents confidence in BMS’ deucravacitinib
Phil Taylor
Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis
0 Comment
Trials leave Galapagos’ SIK programme looking under the weather
Phil Taylor
Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis
0 Comment